Richard E Haaland1, Angela Holder2, Tammy Evans-Strickfaden3, Beatrice Nyagol4, Mumbi Makanga5, Boaz Oyaro6, Felix Humwa7, Tiffany Williams8, Eleanor McLellan-Lemal9, Mitesh Desai10, Michael J Huey11. 1. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: hyw9@cdc.gov. 2. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: fka5@cdc.gov. 3. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: tae0@cdc.gov. 4. KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: Bnyagol@kemricdc.org. 5. KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: mmakanga@kemricdc.org. 6. KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: Boyaro@kemricdc.org. 7. KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya. Electronic address: FHumwa@kemricdc.org. 8. ICF International, Assigned to Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA 30329. Electronic address: wuq0@cdc.gov. 9. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: egm4@cdc.gov. 10. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, USA 30329. Electronic address: gdo5@cdc.gov. 11. Emory University Student Health Services, Emory University School of Medicine, 1525 Clifton Road, Atlanta, GA, USA 30322. Electronic address: mhuey@emory.edu.
Abstract
OBJECTIVE: This study sought to measure residual contraceptive hormone levels in vaginal rings as an adherence marker for monitoring product use in clinical trials. STUDY DESIGN: Residual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were compared to those from 16 women who used NuvaRing® as their contraceptive choice. RESULTS: Twenty-one (81%) clinical trial rings had contraceptive hormone levels within the range of those used as a contraceptive choice. Five returned rings had unused or discordant levels of residual contraceptive hormones. CONCLUSION: Residual vaginal ring drug levels could help assess adherence in clinical trials. Published by Elsevier Inc.
OBJECTIVE: This study sought to measure residual contraceptive hormone levels in vaginal rings as an adherence marker for monitoring product use in clinical trials. STUDY DESIGN: Residual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were compared to those from 16 women who used NuvaRing® as their contraceptive choice. RESULTS: Twenty-one (81%) clinical trial rings had contraceptive hormone levels within the range of those used as a contraceptive choice. Five returned rings had unused or discordant levels of residual contraceptive hormones. CONCLUSION: Residual vaginal ring drug levels could help assess adherence in clinical trials. Published by Elsevier Inc.
Entities:
Keywords:
Adherence; Contraception; HIV; Multipurpose technology; Vaginal ring
Authors: Hans-Joachim Ahrendt; Israel Nisand; Carlo Bastianelli; Maria Angeles Gómez; Kristina Gemzell-Danielsson; Wolfgang Urdl; Birgit Karskov; Luc Oeyen; Johannes Bitzer; Geert Page; Ian Milsom Journal: Contraception Date: 2006-09-27 Impact factor: 3.375
Authors: Ariane van der Straten; Elizabeth R Brown; Jeanne M Marrazzo; Michael Z Chirenje; Karen Liu; Kailazarid Gomez; Mark A Marzinke; Jeanna M Piper; Craig W Hendrix Journal: J Int AIDS Soc Date: 2016-02-04 Impact factor: 5.396
Authors: Annalene Nel; Linda-Gail Bekker; Elizabeth Bukusi; Elizabeth Hellstrӧm; Philip Kotze; Cheryl Louw; Francis Martinson; Gileard Masenga; Elizabeth Montgomery; Nelisiwe Ndaba; Ariane van der Straten; Neliëtte van Niekerk; Cynthia Woodsong Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240
Authors: Randy M Stalter; Thomas R Moench; Kathleen M MacQueen; Elizabeth E Tolley; Derek H Owen Journal: J Int AIDS Soc Date: 2016-05-02 Impact factor: 5.396